GLP-1 Receptor Agonists and Advanced Liver Outcomes in Type 2 Diabetes: Meta-Analysis Data

Twelve comparative real-world cohort studies form the basis of an exploratory meta-analysis on GLP-1 receptor agonists and advanced liver outcomes in adults with type 2 diabetes. The data, compiled by Jing-Hong Hu, includes a primary pooled hazard ratio estimate and was last updated in June 2026. This systematic review emphasizes active-comparator designs and clinically advanced liver endpoints, with evidence identified through a focused search of PubMed/MEDLINE and Embase.

Use Cases

• Replicating the meta-analysis results based on the pooled hazard ratios and confidence intervals provided.
• Assessing study heterogeneity and exchangeability for synthesis based on the described inclusion of twelve comparative studies.
• Evaluating the impact of different comparator strategies on liver outcome estimates as described in the review methodology.

Strengths

• Data is derived from a systematic review of twelve peer-reviewed comparative studies.
• Includes a primary pooled hazard ratio estimate (HR 0.85, 95% CI 0.74–0.98) from four active-comparator studies.
• Published under a permissive CC-BY-4.0 license, allowing for reuse and redistribution.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The evidence is rated as very low certainty due to the observational nature of included studies and potential residual confounding.

Provenance

Source

Jing-Hong Hu via figshare.

Collection Method

Systematic review and exploratory meta-analysis of real-world cohort studies identified through PubMed/MEDLINE and Embase searches.

Time Range

Literature search updated through 25 April 2026.

Freshness

Last updated 2026-06-02 04:21:23; freshness should be verified.